1. Signaling Pathways
  2. Neuronal Signaling
  3. Amyloid-β

Amyloid-β

β-amyloid peptide; Aβ; Abeta

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P1567
    β-Amyloid (10-35), amide
    β-Amyloid (10-35), amide is composed of 26 aa (10-35 residues of the Aβ peptide) and is the primary component of the amyloid plaques of Alzheimer’s disease.
    β-Amyloid (10-35), amide
  • HY-P1524
    β-Amyloid (1-14),mouse,rat
    β-Amyloid (1-14),mouse,rat is a 1 to 14 fragment of Amyloid-β peptide.
    β-Amyloid (1-14),mouse,rat
  • HY-149764
    Aβ42 agonist-2
    99.92%
    Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells.
    Aβ42 agonist-2
  • HY-147387
    DSS30
    Inhibitor
    DSS30 is a P25/CDK5 inhibitor that reduces β-amyloid (Aβ) secretion by inhibiting amyloid precursor protein lyase 1 (BACEl) phosphorylation. DSS30 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.
    DSS30
  • HY-149430
    YIAD-0205
    YIAD-0205 is an orally available Aβ(1?42) aggregation inhibitor. YIAD-0205 demonstrated in vivo efficacy in an AD transgenic mouse model with five familial AD mutations (5XFAD).
    YIAD-0205
  • HY-N3097R
    Pellitorine (Standard)
    Inhibitor
    Pellitorine (Standard) is the analytical standard of Pellitorine (HY-N3097). Pellitorine is a bioactive natural amide compound. Pellitorine can competitively antagonize the activation of TRPV1 by Capsaicin (HY-10448), thereby reducing pain signal transmission. Pellitorine improves cognitive dysfunction by upregulating the BDNF-ERK1/2-CREB and Nrf2-HO-1 pathways. Pellitorine exerts anti-inflammatory and anti-sepsis effects by inhibiting the release of high mobility group protein B1 (HMGB1) and the expression of RAGE/TLR4. Pellitorine exerts its antithrombotic effect by prolonging the clotting time, inhibiting the activity of clotting factors and thrombin. Pellitorine inhibits lipid peroxidation and resists ferroptosis by upregulating GPX4 and DHODH. Pellitorine kills Aedes aegypti mosquito larvae by inhibiting V-type H⁺-ATPase and aquaporin 4 (AaAQP4). Pellitorine exhibits anti-cancer activity (e.g., leukemia and breast cancer) and has inhibitory effects on certain bacteria.
    Pellitorine (Standard)
  • HY-P4808
    PHF6
    PHF6 (VQIVYK) is a self-assembly sequence capable of initiating the full-length tau protein aggregation and is mapped to the third microtubule-binding repeat region of the tau protein.
    PHF6
  • HY-P1521
    β-Amyloid (15-21)
    β-amyloid (15-21) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.
    β-Amyloid (15-21)
  • HY-169268
    Aβ-IN-10
    Inhibitor
    Aβ-IN-10 (Compound Alz -5) is a bifunctional copper chelator and an inhibitor for beta-amyloid (), that interacts with Aβ aggregates and reduces the neurotoxicity. Aβ-IN-10 exhibits antioxidant efficacy, reveals moderate cytotoxicity with the presence of CuCl2 in SH-SY5Y and HepG2 with IC50 of 65.5, 31.2 μM. Aβ-IN-10 reduces the increase of cell stiffness caused by Aβ.
    Aβ-IN-10
  • HY-P4894
    Amyloid β-Protein (5-42)
    Amyloid β-Protein (5-42) is aAβ Fragment.
    Amyloid β-Protein (5-42)
  • HY-146139
    Aβ-IN-3
    Inhibitor
    Aβ-IN-3 (compound 1) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-3 inhibits Aβ42 aggregation. However, Aβ-IN-3 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-3 can not change the aggregation state of Aβ42 into a nontoxic one.
    Aβ-IN-3
  • HY-W721681
    Dehydro nicardipine
    Inhibitor
    Dehydro nicardipine is a dihydropyridine metabolite of Nicardipine (HY-12515) and belongs to the dihydropyridine class of compounds. Dehydro nicardipine can selectively inhibit the aggregation of Aβ monomers, specifically regulate the extension and binding of Aβ soluble aggregates, change the morphology of Aβ aggregates, and inhibit the growth of aggregate length. Dehydro nicardipine can be used in the study of Alzheimer's disease (AD).
    Dehydro nicardipine
  • HY-123485
    PPI-1019
    Inhibitor
    PPI-1019 is an amyloid beta (Aβ) inhibitor. PPI-1019 can be used in the research of neurological diseases and Alzheimer's disease.
    PPI-1019
  • HY-146314
    MAO-B-IN-9
    Inhibitor 99.70%
    MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent MAO-B (monoamine oxidase B) inhibitor, with an IC50 of 0.18 μM. MAO-B-IN-9 prevents Aβ1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ1-42 anti-aggregation effects. MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MAO-B-IN-9
  • HY-P1854
    β-Amyloid (1-9)
    β-Amyloid (1-9), an N-terminal fragment of beta amyloid, consists of amino acid residues 1 to 9. β-Amyloid (1-9) contains a B cell epitope, but it does not include T cell epitopes. Omission of residues 1 to 9 from the full-length Alzheimer'sβ-Amyloid peptide 1 to 40 does not prevent the peptide from forming amyloid fibrils or eliminate fibril polymorphism .
    β-Amyloid (1-9)
  • HY-W004287R
    Methyl tridecanoate (Standard)
    Inhibitor
    Methyl tridecanoate (Standard) is the analytical standard of Methyl tridecanoate. This product is intended for research and analytical applications. Methyl tridecanoate moderately inhibits β-amyloid aggregation. Methyl tridecanoate weakly inhibits acetylcholinesterase (AChE).
    Methyl tridecanoate (Standard)
  • HY-P10611
    [D-Ser14]-Humanin
    [D-Ser14]-Humanin is a bioactive peptide in which the Ser14 residue of Humanin (HY-P1928) is changed from L-form to D-form. [D-Ser14]-Humanin has potent inhibitory activity against the fibrillation of amyloid-β. Humanin (HY-P1928) inhibits the aging-related death of various cells caused by amyloid fibrils and oxidative stress, and [D-Ser14]-Humanin has better cell protection activity than Humanin (HY-P1928). [D-Ser14]-Humanin can be used in the study of Alzheimer's disease.
    [D-Ser14]-Humanin
  • HY-P0265F
    Biotin-Ahx-β-Amyloid (1-40)
    Biotin-Ahx-β-Amyloid (1-40) is a biological active peptide. (Biotin labled HY-P0265)
    Biotin-Ahx-β-Amyloid (1-40)
  • HY-P4640
    (Lys22)-Amyloid β-Protein (1-42)
    (Lys22)-Amyloid β-Protein (1-42) is a mutation of WT Amyloid β-Protein (1-42) peptide.
    (Lys22)-Amyloid β-Protein (1-42)
  • HY-149246
    Aβ-IN-6
    Inhibitor
    Aβ-IN-6 reduces pro-inflammatory cytokine release from microglia cells. Aβ-IN-6 significantly induces Nrf2 nuclear translocation and hamperes Aβ oligomers formation. Aβ-IN-6 exerts a consistent neuroprotective effect by modulating the redox-sensitive signalling pathways in vivo oxidative stress model. Aβ-IN-6 is an orally active and has antiinflammatory, Antioxidant and Anti-oligomeric activity. Aβ-IN-6 has the potential for Alzheimer's disease (AD) research.
    Aβ-IN-6
Cat. No. Product Name / Synonyms Application Reactivity